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TREM-1–expressing macrophages are significantly increased in the inflamed 































































due  to  the acute  inflammatory process, we also 
detected increased frequencies of TREM-1–express-
ing cells on immunostained sections from patients 
with  chronic  IBD  (Figure  1A).  Double  immu-
nofluorescent  stains  of  frozen  tissue  sections 
using CD68 as a cytoplasmic marker for macro-































In IBD patients, aberrant TREM-1 expression on intes-
tinal macrophages mediates enhanced secretion of proin-












TREM-1–expressing macrophages are increased in the intestinal lamina propria of IBD 
patients. (A) Serial frozen sections of the intestine from normal donors and IBD (CD 
and UC) patients with active disease were immunostained for TREM-1 and CD68. An 
isotype-matched irrelevant mAb was used as a negative control (Isotype ctrl). Stainings 
are representative of at least 12 different intestinal tissue samples for the normal small 
and large intestine and of at least 10 tissues each for UC and CD. Original magnifica-
tion, ×40. (B) Double immunofluorescence stainings demonstrate that most TREM-1– 
positive cells (green) in the intestinal lamina propria from patients with active IBD (UC 
and CD) were CD68+ macrophages (red). Original magnification, ×100.
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Extent of TREM-1 expression in the intestinal mucosa is related to disease 































TREM-1–expressing macrophages are increased in the affected intes-
tinal mucosa of patients with IBD and coexpress CD14 and CD89. (A) 
Lamina propria macrophages of normal intestinal tissue specimens 
and of patients with active IBD were isolated and analyzed by FACS for 
TREM-1, CD14, and CD89 cell-surface expression. (B) Coexpression of 
CD14 and CD89 on TREM-1–positive intestinal macrophages is shown 
for a representative UC patient. (C) The frequency of TREM-1–express-
ing lamina propria macrophages is significantly increased in patients 
with IBD (n = 18: UC, n = 7; CD, n = 11) compared with normal individu-
als (n = 12). Percentages are indicated as mean ± SEM; ***P < 0.001.
Figure 3
Secretion of TNF, IL-6, IL-8 (CXCL8), 
monocyte chemoattractant protein–1 
(MCP-1 [CCL2]), and IL-1β is significantly 
enhanced following engagement of TREM-1 
on intestinal lamina propria macrophages 
from IBD but not from normal control 
patients. Intestinal macrophages isolated 
from CD patients (n = 11), UC patients 
(n = 7), and normal control patients (n = 5) 
were cultured for 24 hours in the presence 
(black bars) or absence (white bars) of an 
agonistic plate-bound anti–TREM-1 mAb. 
Cytokine concentrations were measured 
simultaneously in the supernatant. Data 
represent mean ± SEM; *P < 0.05.
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Blocking TREM-1 attenuates intestinal inflammation in ani-


























Enhanced disease activity is associated with increased TREM-1 mRNA expres-
sion in the intestinal mucosa of patients with IBD. RNA was isolated from endo-
scopic biopsies of actively inflamed intestinal mucosa and of macroscopically non-
affected areas from CD and UC patients and from normal control samples. (A) 
Semiquantitative RT-PCR was performed for TREM-1 and TNF. Amplification of 
GAPDH is shown as an internal control. One representative example is shown for 
5 normal, 11 CD, and 7 UC patients analyzed. (B) TREM-1 mRNA levels were 
analyzed by quantitative RT-PCR. The cycle number at which the TREM-1 tran-
scripts were detectable was compared with that of GAPDH as an internal control 
and expressed as arbitrary units; indicated are the mean values (± SEM) from at 
least 6 tissue samples per group. **P < 0.01; *P < 0.05.
Figure 5
TREM-1 mRNA and protein expression in the colon correlates with colonic inflammation and is induced early during onset of experimental colitis. 
(A) Kinetics of TREM-1 and TNF transcription in the colon upon colitis induction by CD4+ T cell transfer into RAG2–/– recipient mice (transfer 
model) and the DSS mouse model of intestinal inflammation in C57BL/6 mice. β-Actin was used as a loading control. (B) Western blot analyses 
of colonic tissue samples adjacent to those used for RNA isolation demonstrate the increased TREM-1 protein expression during induction of 
colitis. Tubulin is shown as a control. (C) H&E-stained paraffin-embedded tissue sections demonstrate the onset of histopathological alterations 
after 5 days after cell transfer and after 3 days after DSS administration. Original magnification, ×40. In each model 4 mice were analyzed per 
time point in 2 independent experiments.
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Blocking TREM-1 attenuates intestinal inflammation in 2 distinct mouse models of colitis. Colitis was induced either by the transfer of splenic 
CD4+CD45RBhi T cells into RAG2–/– recipients (top row) or by oral administration of DSS (bottom row). Upon colitis induction, experimental mice 
were treated daily either with an antagonistic TREM-1 peptide (LP17) or with a control peptide. (A) Fecal samples from each mouse were tested 
for the presence of occult blood and bloody diarrhea to obtain the stool consistency score (see Methods). Data are presented as mean ± SEM; 
n = 10. (B) The colon length of each mouse was measured from the end of the cecum to the anus; indicated are the mean loss of colon length 
(%) at the end of the experiment. (C) The colitis scores for the 2 groups (LP17-treated and control-treated) were determined as described in 
Methods. (D) PCR analysis for TREM-1 and TNF mRNA was performed on identical segments of the distal colon in untreated mice (RAG2–/–; 
C57BL/6 [B6]) and antagonistic TREM-1– (LP17-) and control peptide–treated mice upon colitis induction. β-Actin was used as loading control. 
Results for 1 representative unmanipulated control mouse and 2 representative experimental mice per group are shown. ***P < 0.001; n = 10.
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Blocking TREM-1 attenuates the disease process in established colitis. (A) When after oral administration of DSS the experimental mice devel-
oped colitis with persistent diarrhea and fecal samples had tested positive for the presence of occult blood (day 3), the first group of mice was 
analyzed (day 3; n = 8), and the remaining experimental mice were treated daily with either antagonistic TREM-1 peptide (LP17; n = 8) or with 
control peptide (n = 8) for an additional 5 days. (B) Fecal samples from each mouse were tested for the presence of occult blood and bloody 
diarrhea to obtain the stool consistency score (see Methods). Data are indicated as mean ± SEM; n = 8. (C) The colonic length in each mouse 
was measured from the end of the cecum to the anus; indicated are the mean loss of colon length (%) on day 3 and on day 9 for both the LP17-
treated and control-treated groups. (D) Colitis scores for the 3 groups of mice were determined as described in Methods. (E) Real-time RT-PCR 
analyses for TREM-1 and TNF mRNA were performed individually on identical segments of the distal colon from each mouse in all experimental 
groups. ***P < 0.001; **P < 0.01; *P < 0.05.
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macrophage population. Such a  low recovery of  transferred 






















































































































Downloaded from http://www.jci.org on July 22, 2015.   http://dx.doi.org/10.1172/JCI30602
research article





















































































































































Downloaded from http://www.jci.org on July 22, 2015.   http://dx.doi.org/10.1172/JCI30602
research article
3106	 The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 117      Number 10      October 2007
169:7–15.
  18. Okayasu,  I.,  et al. 1990. A novel method  in  the 






  20. Gibot,  S.  2006.  Soluble  triggering  receptor 
expressed on myeloid cells and the diagnosis of 













  24. Bleharski,  J.R., et al. 2003. A role  for triggering 
receptor  expressed  on myeloid  cells-1  in  host 














attenuates macrophage  activation.  J. Immunol. 
177:3520–3524.











disease. Eur. J. Gastroenterol. Hepatol. 9:893–899.
  32. Smith,  P.D.,  Ochsenbauer-Jambor,  C.,  and 


















Downloaded from http://www.jci.org on July 22, 2015.   http://dx.doi.org/10.1172/JCI30602
